Similar articles

• A small molecule-kinase interaction map for clinical kinase inhibitors.

  Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ. Fabian MA, et al. Nat Biotechnol. 2005 Mar;23(3):329-36. doi: 10.1038/nbt1068. Epub 2005 Feb 13. Nat Biotechnol. 2005. PMID: 15711537
• Interaction maps for kinase inhibitors.

  Griffin JD. Griffin JD. Nat Biotechnol. 2005 Mar;23(3):308-9. doi: 10.1038/nbt0305-308. Nat Biotechnol. 2005. PMID: 15765084 No abstract available.
• Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.

  Namboodiri HV, Bukhtiyarova M, Ramcharan J, Karpusas M, Lee Y, Springman EB. Namboodiri HV, et al. Biochemistry. 2010 May 4;49(17):3611-8. doi: 10.1021/bi100070r. Biochemistry. 2010. PMID: 20337484
• New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

  O'Hare T, Eide CA, Deininger MW. O'Hare T, et al. Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865. Expert Opin Investig Drugs. 2008. PMID: 18491988 Review.
• Overcoming kinase resistance in chronic myeloid leukemia.

  Lee F, Fandi A, Voi M. Lee F, et al. Int J Biochem Cell Biol. 2008;40(3):334-43. doi: 10.1016/j.biocel.2007.10.001. Int J Biochem Cell Biol. 2008. PMID: 18401881 Review.